Vernalis is a development stage pharmaceutical company with significant expertise both in de novo fragment and structure-based drug discovery and pre-clinical and clinical development.

The Group has seven product candidates in clinical development (two of which are partnered), two programmes in pre-clinical (one with a partner) and other competitive research programmes.